Zimmer Biomet Holdings, Inc. (ZBH) traded negative at $118.06. On an intraday basis, the price dropped -0.28 points or -0.23%. The composite uptick value was $8.59 million while the combined downtick value was $6.35. The net money flow was $2.24 million while the up/down ratio was not very comforting at 1.35. The shares on a weekly note has seen a change in share price of 0.94%.According to the trading data, the shares saw a block trade with $2.85 million in upticks and $0 million in downticks. The up/down ratio for the block was calculated to be 0. The net money flow for the block trade was 2.85.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Zimmer Biomet Holdings, Inc. rose by 2.22% in the last five trading days and 14.84% for the last 4 weeks. Zimmer Biomet Holdings, Inc. is up 12.7% in the last 3-month period. Year-to-Date the stock performance stands at 14.84%. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) rose 0.15% or 0.18 points on Wednesday and made its way into the gainers of the day. After trading began at $118.81 the stock was seen hitting $119.25 as a peak level and $117.35 as the lowest level. The stock ended up at $118.51. The daily volume was measured at 1,461,410 shares. The 52-week high of the share price is $133.21 and the 52-week low is $88.27. The company has a market cap of $23,738 million.
Company has reported several Insider transactions to the SEC, on Dec 5, 2016, David A. Jr. Nolan (Group President) sold 5,050 shares at 101.11 per share price.On Sep 9, 2016, Daniel E. Williamson (Group President) sold 2,716 shares at 129.96 per share price.On Aug 24, 2016, Stuart G. Kleopfer (President, Americas) sold 3,397 shares at 129.71 per share price.
Zimmer Biomet Holdings Inc Last issued its quarterly earnings results on Jan 31, 2017. The company reported $2.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $2.11. The company had revenue of $2013.10 million for the quarter, compared to analysts expectations of $2013.08 million. The companys revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.09 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by RBC Capital Mkts on Feb 1, 2017 to Outperform, Raises Price Target to $ 133 from a previous price target of $130 .Company shares were Reiterated by Needham on Jan 26, 2017 to Strong Buy, Raises Price Target to $ 151 from a previous price target of $148 .Zimmer Biomet Holdings Inc was Upgraded by Citigroup to Neutral on Nov 29, 2016.
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States.